Prosecution Insights
Last updated: November 20, 2026
Application No. 18/701,144

INNER EAR ORGANOIDS HAVING IMPROVED HAIR CELL DIFFERENTIATION ABILITY AND METHOD FOR PRODUCING SAME

Final Rejection §102§103§112
Filed
Apr 12, 2024
Priority
Oct 15, 2021 — RE 10-2021-0137546 +1 more
Examiner
MARVICH, MARIA
Art Unit
1634
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ajou University Industry-Academic Cooperation Foundation
OA Round
2 (Final)
55%
Grant Probability
Moderate
3-4
OA Rounds
1y 5m
Est. Remaining
83%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
546 granted / 995 resolved
-5.1% vs TC avg
Strong +28% interview lift
Without
With
+27.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
66 currently pending
Career history
1058
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
27.4%
-12.6% vs TC avg
§102
19.0%
-21.0% vs TC avg
§112
36.2%
-3.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 995 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 2 and 4-7 are pending. This application claims a priority as a 371 filing of PCT/KR022/015663 filed 10/14/2022 which claims priority to KR10-2021-0137546 filed 10/15/2021. A translation of the foreign papers has not been made of record in accordance with 37 CFR 1.55. Therefore the effective filing date of the instant invention is that of the filing of the application on 10/15/2021. Response to Amendments The amendments to the drawings were sufficient to overcome the objections to the drawings. As well, the rejection under 35 USC 112, second and 35 USC 101 are overcome. Claim Rejections - 35 USC § 112, second paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 and 6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. These are new rejections necessitated by applicants’ amendment. Claim 1b) recites the limitation "the cells" in line 5 and 6. There is insufficient antecedent basis for this limitation in the claim. Cells are differentiated into ectoderm, endoderm and otic vesicles. Hence, the reference in lines 5 and again in line 6 are unclear. It is unclear if the reference is made to the original ESC or iPSC of step a) or the ectoderm, the endoderm or the cells of the otic vesicle and in line 6 this would also include the steps that are cultured in N2 media. Claim 1) recites the limitation "the start of differentiation " in line 10. There is insufficient antecedent basis for this limitation in the claim. There is no actual start of differentiation. The cells are induced to form differentiated cells in part a) but there is no actual start of this differentiation such that one would known what day 25, 35, 80 and 90 are. Claim Rejections - 35 USC § 112, first paragraph The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claims 1, 2 and 4-7 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is maintained. The claims broadly refer to steps of culturing that are necessary to produce an inner ear organoid with improved hair cell differentiation ability. The step of culturing is not defined except by the effect of forming endoderm, ectoderm and otic vesicles. The disclosure provides the following specifics which appear to be the sole means by which the method is performed. [0037] ESCs were differentiated into an inner ear-like organoid based on prior literature [Koehler K R, Hashino E. 3d mouse embryonic stem cell culture for generating inner ear organoids. Nature Protocols 2014; 9: 1229-44]. Briefly, on day 3 of differentiation, non-neural ectoderm was induced by adding 10 ng/mL of recombinant BMP4 (Stemgent, Beltsville, MD, USA) and 1 μM SB431542 (Stemgent) to the cultured cells (non-neural ectoderm induction step). On day 5, preplacodal ectoderm was induced by adding 25 ng/mL of FGF-2 (Peprotech, Rocky Hill, NJ, USA) and 1 μM of LDN-193189 (Stemgent) (preplacodal ectoderm induction step). Cells were cultured for 2 days, and the medium was replaced with maturation medium containing 1% Matrigel on day 8 (otic vesicle induction and first maturation step). Half of the medium was replaced with Matrigel-free maturation medium every other day until day 18, and then, the organoid was cultured in the organoid medium (second maturation step). The schematic diagram of the differentiation process is shown in FIG. 1. This is a limited descriptive element wherein the claims broadly and incompletely claim the inventive elements. Specifically, the method of producing the inner ear organoid having improved cell differentiation ability involves specific steps. First, the cells are induced to form ectoderm by addition of BMP4 and SB431542 on day 3. On day 5, FGF-2 and LDN-193189 is added until day 8 at which time Matrigel containing maturation media was added as a first maturation step with subsequent additions of Matrigel-free maturation media. The cells were considered differentiated at this point. A second maturation step was based in culturing the organoid in organoid medium from day 20-34 days wherein for improved hair differentiation, DAPT and CHIR-99021 were added to the second maturation step at day 28. These specific compounds added to the cells for the culturing step were shown to be critical for the resulting product. However, the claims refer to them in generic terms. The Court indicated that while applicants are not required to disclose every species encompassed by a genus, the description of a genus is achieved by the recitation of a precise definition of a representative number of members of the genus, such as by reciting the structure. Structural features that could distinguish the compounds of the claimed genus from others not encompassed by the genus are missing from the disclosure. In this case, there are specific elements referenced but the claims reference these structures with broad generic functional terms that represent a large and diverse genus of elements. To this end, the MPEP provides such guidance (emphasis added). If the application as filed does not disclose the complete structure (or acts of a process) of the claimed invention as a whole, determine whether the specification discloses other relevant identifying characteristics sufficient to describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize applicant was in possession of the claimed invention. For example, if the art has established a strong correlation between structure and function, one skilled in the art would be able to predict with a reasonable degree of confidence the structure of the claimed invention from a recitation of its function. Thus, the written description requirement may be satisfied through disclosure of function and minimal structure when there is a well-established correlation between structure and function. In contrast, without such a correlation, the capability to recognize or understand the structure from the mere recitation of function and minimal structure is highly unlikely. In this latter case, disclosure of function alone is little more than a wish for possession; it does not satisfy the written description requirement. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406 (written description requirement not satisfied by merely providing "a result that one might achieve if one made that invention"); In re Wilder, 736 F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming a rejection for lack of written description because the specification does "little more than outline goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate"). Compare Fonar, 107 F.3d at 1549, 41 USPQ2d at 1805 (disclosure of software function adequate in that art). As recited, the method lacks critical elements that provide necessary function. Response to Arguments Applicants argue that the methods of culturing (the remaining issue in the 112a rejection) is described in the disclosure and also well known in the art. What is described in the disclosure is not a genus of culturing methods. Applicants even provide the limited disclosure in their arguments. “In addition, the maturation and culturing step are fully supported by the specification. The specification (Example 1-1, paragraph [0033]) discloses a specific and complete culturing protocol for inducing endoderm, ectoderm, and otic vesicle (e.g., adding BMP4 and SB431542 on day 3, FGF-2 and LDN-193189 on day 5”. The MPEP sets forth “If a representative number of adequately described species are not disclosed for a genus, the claim to that genus must be rejected as lacking adequate written description under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph.” In this case, the step of culturing is an incredible large genus and the field of developing organoids a complicated art and hence applicants by providing a single species of culturing have not satisfied the written description genus. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 7 is rejected under 35 U.S.C. 102(a)(2) as being anticipated by Wong et al (US 20240060040). This is a new rejection necessitated by applicants’ amendment. Wong et al teach an inner ear organoid with improved hair cell differentiation (see Figure 1 and 10 as well as ¶0023). “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 7 is rejected under 35 U.S.C. 103 as being unpatentable over Longworth-Mills (Methods Mol Biol. 2016 ; 1341: 391–406) in view of Liu et al (Stem cell Reports, 2021, pages 2257-2273). This rejection is maintained as regards claim 7 to which applicants arguments do not extend. Longworth-Mills teach a method of producing inner ear organoids wherein the method involves culturing embryonic stem cells (ESC) in differentiation media (abstract). The culturing leads to endoderm, ectoderm and otic vesicles (see bridging ¶, page 1-2). Liu teach hair cell formation in these differentiated tissues was stimulated by CHIR99021 and DAPT which are WNT signaling activators and g-secretase inhibitors respectively (see page 2261, briding ¶ col 1-2). This is critical as protection and regeneration of the mammalian cochlear hair cells are essential for hearing restoration (see Discussion). (Page 2270, col 1) Instead, inner ear organoids could be obtained by 3D culture and staged induction from human pluripotent stem cells (Koehler et al., 2017). However, only a small proportion of the inner ear organoids contain differentiated hair cells and the induced hair cells from stem cell-derived organoids display vestibular but not cochlear characteristics (Koehler et al., 2017; Liu et al., 2016). Therefore, further optimizations of the human inner ear organoids for robust generation of cochlear hair cells will be a major challenge and a worthy undertaking. Based on such teachings, it would have prima facie been obvious to one of ordinary skill in the art at the time the invention was made to incorporate the steps taught by Liu et al in the methods of Longworth-Mills. Such a modification would have resulted in an inner ear organoid comprising the properties of claim 7. As noted above: 1) inner ear organoids are made by culturing cells to induce formation of endoderm, ectoderm and otic vesicles; 2) hair cell formation is stimulated in an improved method by DAPT and CHIR-99021. Thus, a person of ordinary skill in the art, absent evidence to the contrary, would have reasonably expected that the expanded method would allow improved inner cell formation. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARIA MARVICH whose telephone number is (571)272-0774. The examiner can normally be reached 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached at 571-272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARIA MARVICH/Primary Examiner, Art Unit 1634
Read full office action

Prosecution Timeline

Apr 12, 2024
Application Filed
May 14, 2026
Non-Final Rejection mailed — §102, §103, §112
Aug 14, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799493
PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL
5y 7m to grant Granted Nov 17, 2026
Patent 12799469
COMPOSITIONS AND METHODS FOR TREATING CANCER
5y 5m to grant Granted Nov 17, 2026
Patent 12790382
Compositions and Methods for Treating Cancer with DuoCARs
4y 5m to grant Granted Nov 10, 2026
Patent 12758585
VACCINE COMPRISING NATURAL KILLER CELLS LOADED WITH LIGANDS OF NATURAL KILLER T CELLS AND CANCER ANTIGENS
1y 10m to grant Granted Oct 13, 2026
Patent 12760324
ENGINEERED MUSCLE TARGETING COMPOSITIONS
1y 12m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
55%
Grant Probability
83%
With Interview (+27.8%)
4y 0m (~1y 5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 995 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month